Sexual Health

PT-141

Bremelanotide

FDA-approved centrally-acting sexual dysfunction treatment

Research Status: FDA-approved (Vyleesi, 2019) Bremelanotide Vyleesi PT141
Mechanism of Action

How it works

PT-141 activates melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system, rather than the vascular system like PDE-5 inhibitors. MC4R activation in the hypothalamus drives sexual arousal through dopaminergic pathways.

Areas of Research

What the research explores

In published research, PT-141 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • FDA-approved for hypoactive sexual desire disorder (HSDD) in women (Vyleesi)
  • Centrally acting: works on brain, not blood vessels
  • Effective regardless of hormonal status
  • Studied in men for erectile dysfunction
  • No significant cardiovascular effects
  • Rapid onset via subcutaneous route
Research Highlight

PT-141/Bremelanotide became the first non-hormonal, centrally-acting medication for female sexual dysfunction approved by the FDA in 2019, validating the melanocortin pathway for this indication.

Safety Profile

Adverse events & gaps

FDA-approved with documented safety profile. Transient nausea and flushing; hyperpigmentation possible with repeat use. Avoid in cardiovascular disease.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.